Recent Treatment Patterns of Oropharyngeal Cancer in Korea Based on the Expert Questionnaire Survey of the Korean Society for Head and Neck Oncology (KSHNO)
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of stage T2 OPC according to the N category and determine the opinions of multidisciplinary experts in Korea. Materials and Methods Five OPC scenarios were developed by the Subcommittee on Oropharyngeal Treatment Guidelines of the Korean Society for Head and Neck Oncology and distributed to experts of multidisciplinary treatment hospitals. Results Sixty-five experts from 45 institutions responded. For the HPV-positive T2N0M0 scenario, 67.7% of respondents selected surgery followed by definitive concurrent chemoradiotherapy (CCRT) or radiotherapy alone. For the T2N1M0 HPV-positive scenario, there was a notable difference in the selection of primary treatment by expert specialty; 53.9% of respondents selected surgery and 39.8% selected definitive CCRT as the primary treatment. For the T2N3M0 advanced HPV-positive scenario, 50.0% of respondents selected CCRT and 33.3% considered induction chemotherapy (IC) as the primary treatment. CCRT and IC were significantly more frequently selected for the HPV-related OPC cases (p=0.010). The interdepartmental variability showed that the head and neck surgeons and medical oncologists favored surgery, whereas the radiation oncologists preferably selected definitive CCRT (p < 0.001). Conclusion In this study, surgery was preferred for lymph node-negative OPC, and as lymph node metastasis progressed, CCRT tended to be preferred, and IC was administered. Clinical practice patterns by stage and HPV status showed differences according to expert specialty. Multidisciplinary consensus guidelines will be essential in the future.
Abstract
Purpose The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of stage T2 OPC according to the N category and determine the opinions of multidisciplinary experts in Korea. Materials and Methods Five OPC scenarios were developed by the Subcommittee on Oropharyngeal Treatment Guidelines of the Korean Society for Head and Neck Oncology and distributed to experts of multidisciplinary treatment hospitals. Results Sixty-five experts from 45 institutions responded. For the HPV-positive T2N0M0 scenario, 67.7% of respondents selected surgery followed by definitive concurrent chemoradiotherapy (CCRT) or radiotherapy alone. For the T2N1M0 HPV-positive scenario, there was a notable difference in the selection of primary treatment by expert specialty; 53.9% of respondents selected surgery and 39.8% selected definitive CCRT as the primary treatment. For the T2N3M0 advanced HPV-positive scenario, 50.0% of respondents selected CCRT and 33.3% considered induction chemotherapy (IC) as the primary treatment. CCRT and IC were significantly more frequently selected for the HPV-related OPC cases (p=0.010). The interdepartmental variability showed that the head and neck surgeons and medical oncologists favored surgery, whereas the radiation oncologists preferably selected definitive CCRT (p < 0.001). Conclusion In this study, surgery was preferred for lymph node-negative OPC, and as lymph node metastasis progressed, CCRT tended to be preferred, and IC was administered. Clinical practice patterns by stage and HPV status showed differences according to expert specialty. Multidisciplinary consensus guidelines will be essential in the future.
참고문헌 (30)
- O’Sullivan B, "Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging(ICON-S) : a multicentre cohort study", Lancet Oncol, 17, pp.440~451 (2016)
- Ramqvist T, "Oropharyngeal cancer epidemic and human papillomavirus", Emerg Infect Dis, 16, pp.1671~1677 (2010)
- Chaturvedi AK, "Human papillomavirus and rising oropharyngeal cancer incidence in the United States", J Clin Oncol, 29, pp.4294~4301 (2011)
- Schache AG, "HPV-related oropharynx cancer in the United Kingdom : an evolution in the understanding of disease etiology", Cancer Res, 76, pp.6598~6606 (2016)
- Elrefaey S, "HPV in oropharyngeal cancer : the basics to know in clinical practice", Acta Otorhinolaryngol Ital, 34, pp.299~309 (2014)
- Urban D, "What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?", Cancer, 120, pp.1462~1470 (2014)
- 이수민, "Refining prognostic stratification of human papillomavirus-related oropharyngeal squamous cell carcinoma: different prognosis between T1 and T2", Radiation oncology journal, 35(3), pp.233~240 (2017), 대한방사선종양학회
- Kim YT, "Burden of human papillomavirus(HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea", Papillomavirus Res, 7, pp.26~42 (2019)
- Sher DJ, "Radiation therapy for oropharyngeal squamous cell carcinoma : executive summary of an ASTRO Evidence-Based Clinical Practice Guideline", Pract Radiat Oncol, 7, pp.246~253 (2017)
- Koyfman SA, "Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx : ASCO Clinical Practice Guideline", J Clin Oncol, 37, pp.1753~1774 (2019)
- Psyrri A, "The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck", Ann Oncol, 25, pp.2101~2115 (2014)
- O’Sullivan B, "Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis", J Clin Oncol, 31, pp.543~550 (2013)
- Masterson L, "De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma", Cochrane Database Syst Rev, (2), pp.CD010271~ (2014)
- Denis F, "Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma", J Clin Oncol, 22, pp.69~76 (2004)
- Zumsteg ZS, "Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer", Cancer, 123, pp.1555~1565 (2017)
- Forastiere AA, "Long-term results of RTOG 91-11 : a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer", J Clin Oncol, 31, pp.845~852 (2013)
- Gillison ML, "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer(NRG Oncology RTOG 1016) : a randomised, multicentre, noninferiority trial", Lancet, 393, pp.40~50 (2019)
- Mehanna H, "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer(De-ESCALaTE HPV) : an open-label randomised controlled phase 3 trial", Lancet, 393, pp.51~60 (2019)
- Chera BS, "Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma", Int J Radiat Oncol Biol Phys, 93, pp.976~985 (2015)
- Yom SS, "NRG-HN002 : a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer", Int J Radiat Oncol Biol Phys, 105, pp.684~685 (2019)
- Golusinski W, "Current role of surgery in the management of oropharyngeal cancer", Front Oncol, 9, pp.388~ (2019)
- Palmer MJ, "Controversies in the management of non-small cell lung cancer : the results of an expert surrogate study", Radiother Oncol, 19, pp.17~28 (1990)
- Machtay M, "Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer : an RTOG analysis", J Clin Oncol, 26, pp.3582~3589 (2008)
- Kolokythas A, "Long-term surgical complications in the oral cancer patient: a comprehensive review. Part I", J Oral Maxillofac Res, 1, pp.e1~ (2010)
- "NCCN guidelines for head and neck cancer" (2020)[URL]
- Cohen EE, "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer", J Clin Oncol, 32, pp.2735~2743 (2014)
- Haddad R, "Induction chemotherapy followed by concurrent chemoradiotherapy(sequential chemoradiotherapy)versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer(PARADIGM) : a randomised phase 3trial", Lancet Oncol, 14, pp.257~264 (2013)
- Hitt R, "A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer", Ann Oncol, 25, pp.216~225 (2014)
- Posner MR, "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer", N Engl J Med, 357, pp.1705~1715 (2007)
- Lorch JH, "Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck : longterm results of the TAX 324 randomised phase 3 trial", Lancet Oncol, 12, pp.153~159 (2011)